Table 3.
Changes in the prevalence of the use of specific psychotropic drug groups among adults aged 60-79 years in Germany. National Health Interview and Examination Surveys GNHIES98 (1997–99) and DEGS1 (2008–11)
| GNHIES98a | DEGS1a | Change in % (GNHIES98-DEGS1) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | % | 95% CI | n | % | 95% CI | Unadjusteda | 95% CI | p value | Adjusteda,b | 95% CI | p value | |||||
| 1. All anti-depressants (St. John’s wort and all synthetical antidepressants) | 96 | 6.4 | 5.2 | 7.9 | 173 | 7.9 | 6.5 | 9.5 | 1.4 | -0.6 | 3.4 | .157 | 1.7 | -1.8 | 5.2 | 0.343 |
| 1.1 St. John’s wort (N06AP) | 47 | 2.9 | 2.1 | 3.9 | 27 | 1.1 | 0.8 | 1.7 | -1.7 | -2.7 | -0.8 | <.001 | -5.0 | -7.9 | -2.0 | 0.001 |
| 1.2 All synthetical antidepressants | 54 | 3.9 | 2.9 | 5.2 | 151 | 6.9 | 5.5 | 8.5 | 3.0 | 1.2 | 4.8 | .001 | 6.0 | 2.5 | 9.4 | 0.001 |
| 1.2.1. NSMRIsc (N06AA) | 45 | 3.6 | 2.6 | 4.8 | 80 | 3.8 | 2.8 | 5.2 | 0.3 | -1.3 | 1.8 | .741 | 0.4 | -2.7 | 3.5 | 0.806 |
| 1.2.2. SSRIsd (N06AB) | 3 | 0.3 | 0.1 | 1.0 | 47 | 2.0 | 1.4 | 2.7 | 1.7 | 1.0 | 2.4 | .001 | 4.1 | 2.4 | 5.8 | <.0001 |
| 2. All hypnotics & sedatives (synth., antihistamines and phytoceuticals) | 62 | 3.6 | 2.8 | 4.8 | 98 | 3.3 | 2.6 | 4.3 | -0.3 | -1.6 | 1.0 | .644 | -1.3 | -3.5 | 0.9 | 0.234 |
| 2.1 All synth. (N05C) and antihistamines (N05CM) | 31 | 1.6 | 1.1 | 2.4 | 52 | 1.6 | 1.1 | 2.2 | 0.0 | -0.9 | 0.8 | .921 | -0.1 | -1.7 | 1.4 | 0.861 |
| 2.1.1. Hypnotics & sedatives (N05C) | 31 | 1.6 | 1.1 | 2.4 | 42 | 1.3 | 0.9 | 1.9 | -0.3 | -1.1 | 0.5 | .430 | -0.6 | -2.2 | 0.9 | 0.412 |
| 2.2. All phytoceuticals | 32 | 2.1 | 1.4 | 3.0 | 51 | 1.9 | 1.3 | 2.6 | -0.2 | -1.2 | 0.8 | .703 | -0.6 | -1.9 | 0.6 | 0.307 |
| 2.2.1. Valerian (N05CP) | 28 | 1.8 | 1.2 | 2.7 | 42 | 1.5 | 1.0 | 2.1 | -0.3 | -1.2 | 0.6 | .453 | -0.5 | -1.7 | 0.7 | 0.408 |
| 3. Benzodiazepines and benzodiazepine-related drugs | 64 | 3.9 | 2.9 | 5.2 | 84 | 3.3 | 2.4 | 4.4 | -0.6 | -2.1 | 0.8 | .389 | -2.0 | -5.0 | 0.9 | 0.176 |
| 3.1. Benzodiazepines (N05BA, N05CD, N03AE01) | 57 | 3.7 | 2.8 | 5.0 | 57 | 2.5 | 1.8 | 3.5 | -1.2 | -2.6 | 0.2 | .081 | -3.4 | -6.3 | -0.4 | 0.024 |
| 3.2. Benzodiazepine-related drugs (Z-drugs) (N05CF) | 8 | 0.2 | 0.1 | 0.5 | 28 | 0.8 | 0.5 | 1.3 | 0.6 | 0.2 | 1.0 | .003 | 1.3 | 0.6 | 2.1 | <0.001 |
| 4. All anti-dementia drugs incl. ginkgo biloba | 34 | 2.2 | 1.4 | 3.4 | 97 | 4.2 | 3.3 | 5.4 | 2.0 | 0.7 | 3.3 | .005 | 3.2 | 1.3 | 5.1 | 0.001 |
| 4.1. Ginkgo biloba (N06DP01) | 34 | 2.2 | 1.4 | 3.4 | 88 | 3.8 | 2.9 | 4.8 | 1.6 | 0.3 | 2.8 | .022 | 2.4 | 1.0 | 3.8 | 0.001 |
| 5. Narcotic analgesics (N02A) | 39 | 3.0 | 2.1 | 4.2 | 96 | 4.1 | 3.2 | 5.3 | 1.2 | -0.3 | 2.6 | .121 | 3.9 | 0.5 | 7.3 | 0.026 |
| 6. Anti-epileptics (N03) | 14 | 1.0 | 0.5 | 1.7 | 63 | 2.3 | 1.7 | 3.3 | 1.4 | 0.4 | 2.3 | .008 | 3.6 | 1.7 | 5.5 | <0.001 |
| 7. Antiparkinson drugs (N04) | 19 | 1.1 | .7 | 1.8 | 32 | 1.2 | 0.7 | 2.0 | 0.1 | -0.7 | 0.9 | .806 | -0.1 | -1.4 | 1.3 | 0.934 |
| 8. Anxiolytics (N05B) | 34 | 2.4 | 1.6 | 3.5 | 48 | 2.2 | 1.5 | 3.1 | -0.2 | -1.4 | 1.0 | .751 | -1.2 | -3.2 | 0.9 | 0.268 |
astandardized to the population of 31.12.2010
b adjusted for sex, age group, region, community size, social status, polypharmacy, living alone, recognized disability
cNon-Selective Monoamine Reuptake Inhibitors
dSelective Serotonin Reuptake Inhibitors
Figures in bold denote statistical significance